[{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"NaV1.8 Sodium Channel","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Orion Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Orion Corporation"},{"orgOrder":0,"company":"Jemincare","sponsor":"Rapt Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"JYB1904","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Rapt Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Rapt Therapeutics"},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Genentech"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JMKX003801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JMB2002","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Jemincare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : RPT904

Product Type : Other Large Molecule

Upfront Cash : $35.0 million

December 23, 2024

Lead Product(s) : JYB1904

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase II

Sponsor : Rapt Therapeutics

Deal Size : $707.5 million

Deal Type : Licensing Agreement

blank

02

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMKX003801

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 26, 2023

Lead Product(s) : JMKX003801

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : IND Enabling

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMKX002992

Product Type : Other Small Molecule

Upfront Cash : $60.0 million

August 18, 2022

Lead Product(s) : JMKX002992

Therapeutic Area : Oncology

Highest Development Status : IND Enabling

Sponsor : Genentech

Deal Size : $650.0 million

Deal Type : Licensing Agreement

blank

04

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMKX000623

Product Type : Other Small Molecule

Upfront Cash : $15.8 million

June 05, 2022

Lead Product(s) : JMKX000623

Therapeutic Area : Neurology

Highest Development Status : IND Enabling

Sponsor : Orion Corporation

Deal Size : Undisclosed

Deal Type : Agreement

blank

05

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMKX000623

Product Type : Other Small Molecule

Upfront Cash : $16.1 million

June 05, 2022

Lead Product(s) : JMKX000623

Therapeutic Area : Neurology

Highest Development Status : IND Enabling

Sponsor : Orion Corporation

Deal Size : Undisclosed

Deal Type : Agreement

blank

06

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMB2002

Product Type : Antibody

Upfront Cash : Inapplicable

September 13, 2021

Lead Product(s) : JMB2002

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMB2002

Product Type : Antibody

Upfront Cash : Inapplicable

February 04, 2021

Lead Product(s) : JMB2002

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

08

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details :

Product Name : JMB2002

Product Type : Antibody

Upfront Cash : Inapplicable

January 20, 2021

Lead Product(s) : JMB2002

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank